The proof of concept has exploited the tumor antigen OVA because several tools and specific antibodies are available for the downstream detection of this antigen; the in vitro study highlighted that both AdOVA and PeptiCRAd have elicited the presentation of TAs in an immunogenic fashion as shown by the contemporaneity expression of H2Kb-bound to SIINFEKL and upregulation of CD86 molecule; in details, PeptiCRAd induced immunogenic modulation already 24h post-infection, whereas AdOVA required 48h. The gene discussed is CD86; the disease is infection.